Shark Mouth Modified Pancreaticojejunostomy
NCT03366038 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2018-04-05
Summary
Pancreaticoduodenectomy (PD) is one of the most complicated surgical procedure and one of the standard treatments for benign and malignant disease of pancreatic head and periampullary region. Improvements in surgical techniques and the perioperative management of patients undergoing PD have reduced the surgical mortality rates to less than 3% in high-volume medical centers. However, the incidence of postoperative complication remains high, which ranges from 30% to 50% and the pancreatic fistula rate ranges from 5% to 40%. The key point of PD is still the enteric reconstruction of pancreatic stump. There were different techniques of enteric reconstruction, including: invagination pancreaticojejunostomy, binding pancreaticojejunostomy, duct-to-mucosa pancreaticojejunostomy, Roux-en-Y pancreaticojejunostomy, and pancreaticogastrostomy and each technique had its advantages and disadvantages. We established a new digestive reconstruction technique named shark mouth modified pancreaticojejunostomy, which had theoretical advantages including easier performed; lower tension and less complication. The shark mouth modified pancreaticojejunostomy is an end-to-end pancreaticojejunostomy procedure which is between invagination pancreaticojejunostomy and binding pancreaticojejunostomy.The remnant of jejunum is shaped as shark mouth and then sutured with the pancreas remnant. After the surgery, the patients will be well followed up. The pancreaticojejunostomy time, post-operation complication, mortality and hospital stay will be documented to study the safety, efficiency and advantage of this new procedure.
Conditions
- Pancreatic Cancer
- Periampullary Carcinoma
Interventions
- PROCEDURE
-
Shark Mouth Modified Pancreaticojejunostomy
The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant), which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis. The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis.
Sponsors & Collaborators
-
Peking University Third Hospital
lead OTHER
Principal Investigators
-
Xiu Dainrong, Doctor · Department of General Surgery, Peking University Third Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-12-08
- Primary Completion
- 2019-12-09
- Completion
- 2020-05-01
Countries
- China
Study Locations
More Related Trials
-
Clinical Study Between Robotic and Open Surgery in Patients With Pancreatic Cancer
NCT04211948 ·Status: UNKNOWN ·Phase: NA
-
Conventional Partial Pancreatoduodenectomy Versus an Extended Pancreatoduodenectomy for Pancreatic Head Cancers
NCT06703905 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer
NCT06873178 ·Status: ACTIVE_NOT_RECRUITING
-
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
NCT02850874 ·Status: WITHDRAWN ·Phase: PHASE2
-
Clinical Study on Fecal Microbiota Transplantation for Diarrhea After Total Pancreatectomy
NCT06960122 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer
NCT06326736 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer
NCT03236883 ·Status: UNKNOWN ·Phase: PHASE1
-
The Therapeutic Evaluation(Both Short-term and Long-term Outcome) of Minimal Invasive Radical Antegrade Modular Pancreatosplenectomy for Left-sided Pancreatic Cancer Patients
NCT03770559 ·Status: UNKNOWN ·Phase: NA
-
XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer
NCT07114666 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
NCT02706782 ·Status: UNKNOWN ·Phase: PHASE1
-
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
NCT05723978 ·Status: COMPLETED
-
The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer
NCT03747588 ·Status: RECRUITING ·Phase: NA
-
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
NCT04324307 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
NCT06307080 ·Status: RECRUITING ·Phase: NA
-
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
NCT05607953 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
NCT05185869 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer
NCT05201729 ·Status: UNKNOWN
-
An Open-label, Multicenter, Prospective Study of Irreversible Electroporation (Nano Knife) Combined With Radiotherapy and Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT04310553 ·Status: UNKNOWN ·Phase: NA
-
A Study of Extended Total Mesopancreas Excision(eTME) for Pancreatic Head Adenocarcinoma.
NCT04147403 ·Status: UNKNOWN
-
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
NCT04603586 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
NCT04239001 ·Status: UNKNOWN ·Phase: NA
-
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
NCT06346808 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study
NCT07173374 ·Status: SUSPENDED ·Phase: PHASE1
-
Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
NCT00003025 ·Status: COMPLETED ·Phase: PHASE1
-
PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer
NCT04518800 ·Status: UNKNOWN ·Phase: NA